Company / R&D Expense
Solventum R&D Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$739.0M
FY2025
5-year range
$739.0M / $775.0M
FY2022-FY2025
Trend
-4.6%
vs FY2024
Sector context
#12 of 110
Health Care
What the data says
Solventum's r&d expense of $739M is higher than 89% of companies in the Health Care sector (FY2025). R&D Expense remained relatively stable over the past 4 years, with values between $739M and $775M.
Based on SEC 10-K filings.
$739M in FY2025 with a 3-year CAGR of -1.2%. Top quartile in the Health Care sector.
Declined from $758M to $739M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -1.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 110This company $739.0M Sector average $298.2M
▼
+147.8% above sector average
Key checks
Key Insights
- 3-year CAGR of -1.2%, indicating a declining trend.
- In FY2025, r&d expense decreased 4.6% year-over-year.
- Ranks #12 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 30.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $739.0M | -4.6% |
| FY2024 | $775.0M | +2.2% |
| FY2023 | $758.0M | -1.2% |
| FY2022 | $767.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026